Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865779 | 0.84 | LMNA (0.58) | MAOBLMNAHTTPOLB | |
| SCHEMBL1877453 | 0.82 | POLB (0.64) | EPHX2CA1CA2MLYCDMEN1 | |
| SCHEMBL12085989 | 0.81 | LMNA (0.46) | MAOBNPC1RAB9APKMLMNA | |
| SCHEMBL8612257 | 0.81 | MLYCD (0.58) | EPHX2CA1CA2MLYCDMEN1 | |
| SCHEMBL13701651 | 0.80 | ANO1 (0.58) | ANO1ALDH1A1LMNAGSK3B | |
| SCHEMBL7835765 | 0.79 | MEN1 (0.49) | EPHX2CA1CA2MLYCDMEN1 | |
| SCHEMBL1417979 | 0.79 | HDAC2 (0.57) | EPHX2CA1CA2MLYCDMEN1 | |
| SCHEMBL22099995 | 0.78 | LRRK2 (0.48) | EPHX2EGLN1MEN1KMT2AMAOA | |
| SCHEMBL13590906 | 0.78 | CA1 (0.59) | EPHX2CA1CA2MLYCDMEN1 | |
| SCHEMBL2522600 | 0.78 | LMNA (0.53) | KMT2AMAOBALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0755250-A4 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS INC (US) | 2000-04-19 | — | — | EP | claimed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | claimed |
| US-5472983-A | Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | claimed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | claimed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-0755250-A4 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS INC (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5472983-A | Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | EPHX2 3440/4885EGLN1 2657/4885CA1 1863/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | EPHX2 2830/4885EGLN1 3469/4885CA1 2610/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | EPHX2 3569/4885EGLN1 2756/4885CA1 1963/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | EPHX2 3820/4885EGLN1 1502/4885CA1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.